Bristol Myers Squibb Co. (BMY)
62.32
-0.59
(-0.94%)
USD |
NYSE |
Nov 12, 16:00
62.50
+0.18
(+0.29%)
Pre-Market: 07:17
Bristol Myers Squibb Enterprise Value : 159.61B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 159.61B |
| November 11, 2026 | 160.82B |
| November 10, 2026 | 160.59B |
| November 09, 2026 | 159.24B |
| November 06, 2026 | 159.24B |
| November 05, 2026 | 161.27B |
| November 04, 2026 | 163.43B |
| November 03, 2026 | 158.36B |
| November 02, 2026 | 161.04B |
| October 30, 2026 | 159.94B |
| October 29, 2026 | 157.71B |
| October 28, 2026 | 156.03B |
| October 27, 2026 | 158.04B |
| October 26, 2026 | 158.16B |
| October 23, 2026 | 157.89B |
| October 22, 2026 | 161.00B |
| October 21, 2026 | 157.16B |
| October 20, 2026 | 158.30B |
| October 19, 2026 | 152.48B |
| October 16, 2026 | 154.36B |
| October 15, 2026 | 156.03B |
| October 14, 2026 | 153.40B |
| October 13, 2026 | 148.06B |
| October 12, 2026 | 149.92B |
| October 09, 2026 | 153.07B |
| Date | Value |
|---|---|
| October 08, 2026 | 154.01B |
| October 07, 2026 | 154.26B |
| October 06, 2026 | 154.03B |
| October 05, 2026 | 152.44B |
| October 02, 2026 | 157.22B |
| October 01, 2026 | 157.85B |
| September 30, 2026 | 159.77B |
| September 29, 2026 | 162.41B |
| September 28, 2026 | 164.49B |
| September 25, 2026 | 162.41B |
| September 24, 2026 | 159.63B |
| September 23, 2026 | 158.92B |
| September 22, 2026 | 161.16B |
| September 21, 2026 | 161.92B |
| September 18, 2026 | 162.82B |
| September 17, 2026 | 162.37B |
| September 16, 2026 | 163.92B |
| September 15, 2026 | 164.19B |
| September 14, 2026 | 164.94B |
| September 11, 2026 | 164.00B |
| September 10, 2026 | 164.23B |
| September 09, 2026 | 165.58B |
| September 08, 2026 | 166.15B |
| September 04, 2026 | 170.50B |
| September 03, 2026 | 173.09B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 709.89B |
| Eli Lilly & Co. | 1.388T |
| Merck & Co., Inc. | 406.57B |
| Pfizer Inc. | 213.03B |
| AstraZeneca PLC | 598.18B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.162B |
| Revenue (Quarterly) | 13.08B |
| Total Expenses (Quarterly) | 10.91B |
| EPS Diluted (Quarterly) | 1.053 |
| Gross Profit Margin (Quarterly) | 64.79% |
| Profit Margin (Quarterly) | 16.53% |
| Earnings Yield | 7.24% |
| Operating Earnings Yield | 12.92% |
| Normalized Earnings Yield | 10.24 |